memory consolidation: nootropics and compounds | sci-wiki

ABT-239

Abbott Laboratories built ABT-239 as a drug-like, orally active histamine H3 antagonist with real human-development ambitions behind it, unlike most H3 tool compounds; it was investigated as a candidate for ADHD, Alzheimer's disease, and schizophrenia-related cognitive deficits. It bound the human H3 receptor with subnanomolar potency and more than 1000-fold selectivity over the other histamine receptor subtypes, and it worked in rodent cognition and stress models. Abbott dropped it from human trials after it showed QT interval prolongation, a cardiac liability serious enough to end clinical plans outright, and ABT-239 has since lived on purely as a widely used preclinical benchmark for newer H3 antagonists.

reference

Neuroprotection

BAY 60-7550

BAY 60-7550 is a potent, selective phosphodiesterase-2 (PDE2) inhibitor. By blocking PDE2 it raises both neuronal cAMP and cGMP, driving CREB phosphorylation and BDNF expression while enhancing hippocampal long-term potentiation and memory consolidation. It sits squarely in the cAMP→CREB→BDNF neighborhood but, importantly, acts on PDE2 rather than PDE4, giving it a dual second-messenger action distinct from the more familiar PDE inhibitors.

reference

Nootropic

FK-960

FK-960 was Fujisawa Pharmaceutical's (Japan) 1990s answer to a completely different question than most nootropics of its era: instead of chasing acetylcholine or glutamate receptors, it tried to boost memory by stimulating somatostatin release and, downstream, glial production of GDNF (glial cell line-derived neurotrophic factor). Preclinical work showed it ameliorated memory deficits in rodent models and enhanced hippocampal signaling relevant to long-term potentiation. It moved through animal and early-stage research toward a possible Alzheimer's disease application, but somatostatin-boosting drugs never carved out a clinical niche in dementia care, and FK-960 stalled well short of approval, remembered now mostly in pharmacology reviews as a case study in an alternate route to memory enhancement.

reference

Nootropic

S 38093

Servier, the French pharmaceutical company, developed S 38093 as a histamine H3 receptor antagonist meant to work alongside existing Alzheimer's drugs rather than replace them, stimulating hippocampal neurogenesis and boosting acetylcholine release in a way that looked synergistic with donepezil in aged-mouse models. That preclinical promise carried it into two large international Phase II programs, one alone and one combined with donepezil, enrolling more than 1,300 patients with mild-to-moderate Alzheimer's disease across roughly 40 countries. After a year of dosing at three different levels, none of the arms beat placebo on cognition, function, clinical global impression, or caregiver burden, and treated patients had more falls than those on placebo; Servier discontinued the program on efficacy grounds despite the drug being otherwise reasonably well tolerated.

reference

Nootropic

Suritozole

Suritozole took the opposite approach from a sleeping pill; instead of boosting GABA-A signaling like a benzodiazepine, Marion Merrell Dow (via the MDL research code) built it as a partial inverse agonist at the benzodiazepine site, a molecule meant to dial GABA-A activity down just enough to sharpen memory and arousal without tipping into the anxiety or seizures that full inverse agonists cause. It moved into clinical evaluation for both depression and Alzheimer's-related memory loss in the 1990s, backed by animal data showing it could blunt cognitive impairment after traumatic brain injury in rats. The clinical program quietly stopped without ever producing published efficacy results, leaving it as a research reagent rather than a medicine.

reference